Nucleic Acid-Based Precision Medicines Enabled by the Impilo Platform™.

Prostate cancer is a
high unmet medical need.

Androgen deprivation therapies, enzalutamide and abiraterone used to treat first-line prostate cancer. Resistance eventually develops to CRPC by genomic rearrangements causing constitutive reactivation of the androgen receptor (AR) (Henzler…Dehm, Nature Comms, 2016.). AR splice variants, including AR-V7 function as constitutively active transcription factors to promote resistance to AR-targeted therapies, leaving these patients without effective treatment options.

Prostate cancer remains the second leading cause of male cancer deaths due to disease progression to castration-resistant prostate cancer (CRPC). In the US, there were 288,300 new cases of prostate cancer in 2022, of whom 43,245 progressed on to CRPC.

American Cancer Society, Cancer Statistics, 2023